Laurus Labs stock reached an all-time high of ₹2,137 following strong buying interest from foreign investors. Data shows FPIs now own 30.8% of the company, reflecting confidence in its long-term expansion plans. Investors are now focused on the execution of massive capital projects and the expected growth in the company's contract manufacturing business.
Laurus Labs shares reached a record high of ₹2,137 on Tuesday, as investor interest in the pharmaceutical firm remained strong. The stock has gained 8% over the last two trading sessions, driven by increased trading volumes. This positive momentum comes as data shows that foreign institutional investors have significantly raised their stake in the company.
As of the September 2026 quarter, foreign institutional ownership has climbed to 30.8%, up from 28% in the previous quarter. This buying activity stands in contrast to domestic institutions and retail shareholders, who have trimmed their exposure. The rise in foreign investment reflects growing interest in the company's long-term business strategy, particularly its shift toward more specialized areas of manufacturing.
The company is currently in the middle of a massive expansion phase. It has already invested ₹4,300 crore in its facilities and has another ₹3,000 crore of projects currently under development. The primary goal of this spending is to grow the CDMO business—the segment where the company develops and manufactures drugs for other global pharmaceutical clients. By focusing on specialized areas like peptides, the company aims to move toward higher-value products, which often carry better profit margins than the standard generic API business, which is frequently subject to volatile pricing.
While institutional confidence is high, investors should consider the risks associated with this heavy spending. Large-scale capital projects carry the risk of delays, cost increases, and execution challenges. If the market demand for these new drug products turns out to be weaker than expected, the company may not use its new capacity effectively, which can put pressure on profit margins. Additionally, the significant use of borrowings to fund these projects means the company faces pressure to manage its debt levels. Investors should monitor the debt-to-equity ratio and interest coverage in upcoming quarterly reports to see how the balance sheet is holding up.
Looking ahead, the most critical monitorable for shareholders is the upcoming commissioning of the company's new peptide facility. This facility is expected to be a major contributor to future revenue and will be a key indicator of whether the current expansion strategy is paying off. As the company completes its current cycle of massive capital spending, the market will also look for improved cash flow generation. The company’s ability to meet its long-term growth targets in the contract manufacturing segment will be the primary test for the stock's valuation in the coming years.